Nevoid Malignant Melanoma: A Diagnosis of a Nevus That You Later Regret.

Nevoid Malignant Melanoma: A Diagnosis of a Nevus That You Later Regret. Acta Derm Venereol. 2017 Feb 20;: Authors: Theodosiou G, Johansson I, Hamnerius N, Svensson Å Abstract is missing (Short communication). PMID: 28218335 [PubMed - as supplied by publisher]
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research

Related Links:

AbstractIntravascular dissemination of tumor cells is the accepted mechanism of cancer metastasis. However, the phenomenon of angiotropism, pericyte mimicry (PM), and extravascular migratory metastasis (EVMM) has questioned the concept that tumor cells metastasize exclusively via circulation within vascular channels. This new paradigm of cancer spread and metastasis suggests that metastatic cells employ embryonic mechanisms for attachment to the abluminal surfaces of blood vessels (angiotropism) and spread via continuous migration, competing with and replacing pericytes, i.e., pericyte mimicry (PM). This is an entirely ext...
Source: Angiogenesis - Category: Molecular Biology Source Type: research
AbstractThe neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and Parkinson ’s disease (PD) share some common molecular deficits including disruption of protein homeostasis leading to disease-specific protein aggregation. While insoluble protein aggregates are the defining pathological confirmation of diagnosis, patient stratification based on early molecular etiologies m ay identify distinct subgroups within a clinical diagnosis that would respond differently in therapeutic development programs. We are developing targeted multiple reaction monitoring (MRM) mass spectrometry methods to rigorously quantif...
Source: Journal of Molecular Neuroscience - Category: Neuroscience Source Type: research
Contributors : Pakavarin Louphrasitthiphol ; Colin R GodingSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe MITF and SOX10 transcription factors regulate the expression of genes important for melanoma proliferation, invasion and metastasis. Despite growing evidence of the contribution of long non-coding RNAs (lncRNAs) in melanoma and other cancers, their functions within MITF-SOX10 transcriptional programmes is poorly investigated. Here, we identify 245 candidate melanoma associated lncRNAs whose loci are co-occupied by MITF-SOX10 and are enriched at active enhancer-like regions. W...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
ConclusionsIn patients with RA, the relative increase in etanercept-associated risk of experiencing congestive heart failure, serious infection, non-melanoma skin cancer, or interstitial lung disease was similar between elderly and non-elderly.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
Cell Death &Disease, Published online: 11 November 2019; doi:10.1038/s41419-019-2090-3Long noncoding RNA LINC00518 acts as a competing endogenous RNA to promote the metastasis of malignant melanoma via miR-204-5p/AP1S2 axis
Source: Cell death and disease - Category: Internal Medicine Authors: Source Type: research
Recently, immune checkpoint therapy was shown to be very effective in the treatment of several cancers by reactivating the immune system. This was also shown for hard to treat cancers such as melanoma and lung cancer. At the forefront of immune checkpoint therapy are antibodies targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed cell death-1 (PD-1). However, clinical success of immune checkpoint inhibitors greatly varies between different cancer types, ranging from objective responses in 65-87% of Hodgkin lymphoma (HL) patients to around 30% in other malignancies [reviewed by [1 –3]].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research
Contributors : Bihui Xu ; Zilu ZhouSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe delineate subclonal expansion in a mouse melanoma models in response to immunotherapy, highlighting the role of neoantigens
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Publication date: Available online 9 November 2019Source: International Journal of PharmaceuticsAuthor(s): Aurélie Paganin-Gioanni, Marie-Pierre Rols, Justin Teissié, Muriel GolzioAbstractRNA interference (RNAi) represents a promising therapy for the specific inhibition of gene expression in targeted tissues including tumors. To realize the therapeutic potential of RNAi drugs, non-immunogenic, efficient, and tissue-specific delivery technologies must be developed. We have previously shown that pulsed electric field (PEF) can deliver siRNAs into tumor cells thanks to long electrophoretic drift occurring during...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
AbstractNivolumab is a fully human monoclonal antibody that inhibits programmed cell death ‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐small cell lung cancer, renal cell carcinoma, or small cell lung cancer who rec eived nivolumab as monotherapy or in combination with ipilimumab or chemotherapy across 25 clinical studies. Nivolumab CL was similar across the tumor types examined; CL was higher for ipilimumab 1 mg/kg every 6 weeks (by 17%) and 3 mg/kg...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
AbstractIpilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time ‐varying clearance (CL) was assessed by a population pharmacokinetics (PPK) model developed using statistically significant covariates identified in a previous PPK analysis plus additional covariates. Data from 3,411 patients who received ipilimumab 0.3–10 mg/kg alone or in combination with niv olumab in 16 clinical trials were analyzed. Ipilimumab CL decreased over time; the ch...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
More News: Cancer & Oncology | Dermatology | Melanoma | Skin Cancer